Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis

Neoplasia

Volumn 12, Issue 9, 2010, Pages 718-726

  Toneff, Michael J ^a   Du, Zhijun ^a   Dong, Jie ^a   Huang, Jian ^a   Sinai, Parisa ^b   Forman, James ^b   Hilsenbeck, Susan ^a   Schiff, Rachel ^a   Huang, Shixia ^a   Li, Yi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; GROWTH FACTOR; TAMOXIFEN; VIRUS MIDDLE T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CELL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MODEL; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; OVARIECTOMY; OVARY FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RETROVIRUS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 77956826481     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10516     Document Type: Article

References (54)

1. Clarke RB, Howell A, Potten CS, and Anderson E (1997). Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57, 4987-4991.
2. Ciarloni L, Mallepell S, and Brisken C (2007). Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA 104, 5455-5460.
3. Mallepell S, Krust A, Chambon P, and Brisken C (2006). Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci USA 103, 2196-2201.
4. Allred DC, Brown P, and Medina D (2004). The origins of estrogen receptor alpha-positive and estrogen receptor-negative human breast cancer. Breast Cancer Res 6, 240-245.
5. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, et al. (2009). Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 101, 384-398.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
7. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, and Kern FG (1997). Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogenindependent growth and apoptosis. Oncogene 15, 423-435.
8. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, and Schiff R (2006). Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66, 8266-8273.
9. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, and Schiff R (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68, 826-833.
10. Liu Y, el-Ashry D, Chen D, Ding IY, and Kern FG (1995). MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifensensitivity in vivo. Breast Cancer Res Treat 34, 97-117.
11. Miller DL, el-Ashry D, Cheville AL, Liu Y, McLeskey SW, and Kern FG (1994). Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 5, 1263-1274.
12. Menard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, and Balsari A (2000). Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 60, 273-275.
13. Anisimov VN, Popovich IG, Alimova IN, Zabezhinski MA, Semenchenko AV, and Yashin AI (2003). Number of pregnancies and ovariectomy modify mammary carcinoma development in transgenic HER-2/neu female mice. Cancer Lett 193, 49-55.
14. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, and Hennighausen L (2001). Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10, 545-553.
15. Chen H, Lee JS, Liang X, Zhang H, Zhu T, Zhang Z, Taylor ME, Zahnow C, Feigenbaum L, Rein A, et al. (2008). Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res 68, 3637-3644.
16. Mukherjee S, Louie SG, Campbell M, Esserman L, and Shyamala G (2000). Ductal growth is impeded in mammary glands of C-neu transgenic mice. Oncogene 19, 5982-5987.
17. Cato AC, Henderson D, and Ponta H (1987). The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. EMBO J 6, 363-368.
18. Ham J, Thomson A, Needham M, Webb P, and Parker M (1988). Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. Nucleic Acids Res 16, 5263-5276.
19. PittiusCW, Sankaran L, Topper YJ, and Hennighausen L (1988). Comparison of the regulation of the whey acidic protein gene with that of a hybrid gene containing the whey acidic protein gene promoter in transgenic mice. Mol Endocrinol 2, 1027-1032.
20. Reddy JP and Li Y (2009). The RCAS-TVA system for introduction of oncogenes into selected somatic mammary epithelial cells in vivo. J Mammary Gland Biol Neoplasia 14, 405-409.
21. Du Z, Podsypanina K, Huang H, McGrath A, Toneff MJ, Bogoslovskaia E, Zhang X, Moraes RC, Fluck MM, Allred DC, et al. (2006). Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci USA 103, 17396-17401.
22. Du Z and Li Y (2007). RCAS-TVA in the mammary gland: an in vivo oncogene screen and a high fidelity model for breast transformation? Cell Cycle 6, 823-826.
23. Reddy JP, Peddibhotla S, Bu W, Zhao J, Haricharan S, Du YC, Podsypanina K, Rosen JM, Donehower LA, and Li Y (2010). Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc Natl Acad Sci USA 107, 3728-3733.
24. Holland EC, Li Y, Celestino J, Dai C, Schaefer L, Sawaya RA, and Fuller GN (2000). Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle Tantigen in vivo. Am J Pathol 157, 1031-1037.
25. Bargmann CI andWeinberg RA (1988). Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7, 2043-2052.
26. Khurana B and Kristie TM (2004). A protein sequestering system reveals control of cellular programs by the transcriptional coactivator HCF-1. J Biol Chem 279, 33673-33683.
27. Himly M, Foster DN, Bottoli I, Iacovoni JS, and Vogt PK (1998). The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology 248, 295-304.
28. Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, Foster DN, Federspiel MJ, andHughes SH (1998). The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology 248, 305-311.
29. Nguyen D-A, Beeman N, Lewis M, Schaack J, and Neville MC (2000). Intraductal injection into the mouse mammary gland. In Methods in Mammary Gland Biology and Breast Cancer Research. MM Ip and BB Asch (Eds). Kluwer Academic, New York, NY. pp. 259-270.
30. Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, and Li Y (2005). Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 24, 4220-4231.
31. Hughes SH (2004). The RCAS vector system. Folia Biol (Praha) 50, 107-119.
32. Rodriguez-Viciana P, Collins C, and Fried M (2006). Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc Natl Acad Sci USA 103, 19290-19295.
33. Maynard PV, Davies CJ, Blamey RW, Elston CW, Johnson J, and Griffiths K (1978). Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer 38, 745-748.
34. McCarty KS Jr, Barton TK, Fetter BF, Woodard BH, Mossler JA, Reeves W, Daly J, Wilkinson WE, and McCarty KS Sr (1980). Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma. Cancer 46, 2851-2858.
35. Millis RR (1980). Correlation of hormone receptors with pathological features in human breast cancer. Cancer 46, 2869-2871.
36. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, et al. (2002). The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62, 6376-6380.
37. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, et al. (2000). The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19, 1020-1027.
38. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, and Lydon J (2003). Hormone dependence in premalignant mammary progression. Cancer Res 63, 1067-1072.
39. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, et al. (2003). Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95, 142-153.
40. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, and Slamon DJ (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435-2446.
41. Tsai EM, Wang SC, Lee JN, and Hung MC (2001). Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 61, 8390-8392.
42. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, and Stoica A (2003). Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17, 818-830.
43. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, et al. (2003). Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22, 7998-8011.
44. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, et al. (1997). HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15, 1513-1525.
45. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, and Schiff R (2004). Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96, 926-935.
46. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, and Schiff R (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95, 353-361.
47. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad M, Cowin P, Werb Z, et al. (2003). Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100, 15853-15858.
48. Henry MD, Triplett AA, Oh KB, Smith GH, and Wagner KU (2004). Parityinduced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. Oncogene 23, 6980-6985.
49. Ursini-Siegel J, Schade B, Cardiff RD, and Muller WJ (2007). Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7, 389-397.
50. Jeselsohn R, Brown NE, Arendt L, Klebba I, Hu MG, Kuperwasser C, and Hinds PW (2010). Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 17, 65-76.
51. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15, 907-913.
52. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, and Weinberg RA (2007). Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12, 160-170.
53. Yue W, Wang J, Savinov A, and Brodie A (1995). Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 55, 3073-3077.
54. de Lima GR, Facina G, Shida JY, Chein MB, Tanaka P, Dardes RC, Jordan VC, and Gebrim LH (2003). Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 39, 891-898.